Evidence map›Paper›PMID 40094425›Full record

ArticleNano letters2025

Metal-Organic Frameworks-Based Microrockets for Controlled and Sustained Drug Release.

Zixi Wan, Casper H Y Chung, Chi Ming Laurence Lau, Jin Teng Chung, Ying Chau, Zhiyong Fan, Shuaizhong Zhang, Shuhuai Yao

Abstract read
In one paragraph

Article in Nano letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zixi WanDepartment of Mechanical and Aerospace Engineering, The Hong Kong University of Science and Technology, Hong Kong, SAR, China.ORCID 0000-0002-0493-480X
Casper H Y ChungDepartment of Mechanical and Aerospace Engineering, The Hong Kong University of Science and Technology, Hong Kong, SAR, China.ORCID 0000-0001-5868-7712
Chi Ming Laurence LauDepartment of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Hong Kong, SAR, China.
Jin Teng ChungDepartment of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Hong Kong, SAR, China.ORCID 0000-0002-2085-0008
Ying ChauDepartment of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Hong Kong, SAR, China.ORCID 0000-0003-1759-934X
Zhiyong FanDepartment of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Hong Kong, SAR, China.ORCID 0000-0002-5397-0129
Shuaizhong ZhangDepartment of Mechanical and Aerospace Engineering, The Hong Kong University of Science and Technology, Hong Kong, SAR, China.ORCID 0000-0002-4103-1474
Shuhuai YaoDepartment of Mechanical and Aerospace Engineering, The Hong Kong University of Science and Technology, Hong Kong, SAR, China.ORCID 0000-0001-7059-4092

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastritis, linked to chronic stress and poor diets, poses significant risks, including ulcers and gastric cancers. Current treatments involving frequent dosing of multiple drugs face challenges with patient nonadherence and antibiotic resistance. To overcome these issues, metal-organic framework (MOF)-based microrockets utilizing a zinc-powered engine were engineered with pH-sensitive coatings for targeted gastritis treatment. These microrockets can self-propel into the gastric mucus via bubble propulsion and slowly release pharmaceutical ingredients from MOF components. A poly(3,4-ethylenedioxythiophene) shell and pH-sensitive enteric coating is designed for protection of MOFs in acid while allowing sustained drug release at the mucosa's neutral pH. In vivo studies demonstrate these microrockets sustain a prolonged drug retention for 48 h. This biocompatible design represents a promising strategy for active and controlled drug delivery with sustained release in acidic environments, presenting the potential for diverse biomedical applications.

Indexed as

Delayed-Action PreparationsMetal-Organic FrameworksAnimalsBridged Bicyclo Compounds, HeterocyclicDrug Delivery SystemsDrug LiberationHumansHydrogen-Ion ConcentrationPolymersZincBridged Bicyclo Compounds, HeterocyclicDelayed-Action PreparationsMetal-Organic Frameworkspoly(3,4-ethylene dioxythiophene)PolymersZinccontrolled and sustained releasedrug deliverymetal−organic frameworks (MOFs)microrocketspH-response

Identifiers

PMID40094425
PMCPMC12007105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.